Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx NV is advancing its clinical-stage product candidate, vilobelimab, a novel anti-C5a monoclonal antibody, demonstrating promising efficacy in treating autoimmune and inflammatory conditions. Clinical data indicate that vilobelimab significantly improves health scores, reduces disease severity, and enhances patient outcomes, with a marked reduction in all-cause mortality in treated populations. The therapy's ability to improve patient responses while being well tolerated indicates a strong potential for both clinical and commercial success as additional investigations are warranted.

Bears say

InflaRx NV faces a negative outlook primarily due to depressed forward multiples that are reflective of current market volatility, indicating potential challenges in attracting investor confidence. Additionally, the company's cash burn could significantly escalate as it navigates the various stages of development programs, with limited offset from partner or collaborative milestone revenues. Furthermore, there is a concerning commercial risk associated with partnered assets, which may experience diminishing demand and reduced market share due to evolving standards of care and competition from emerging therapies.

InflaRx (IFRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 5 analysts, InflaRx (IFRX) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.